Comparing the two trials, intensifying therapy for patients with IKZF1 deletions, including the addition of imatinib for those with Ph+ ALL, improved the 5-year overall survival from 69.6% to 91.6% [84]. Here, IKZF1 is linked to acute lymphoblastic leukemia.